Fig. 1.
Fig.2.
Fig. 3.
Laboratory parameters at T0 and T12 excluding patients with diabetes, systemic arterial hypertension, chronic kidney disease and acute renal failure (n = 49)
| Variables | T0 | T12 | p |
|---|---|---|---|
| Creatinine (mg/dL) | 0.95 ± 0.2 | 1.10 ± 0.2 | 0.007 |
| Urea (mg/dL) | 37 ± 15 | 40 ± 13 | 0.343 |
| Sodium (Na) (mmol/L) | 137 ± 3 | 141 ± 3 | < 0.001 |
| Potassium (k) (mmol/L) | 4.00 ± 0.6 | 4.36 ± 0.4 | 0.032 |
| Glucose (mg/dL) | 113 ± 20 | 103 ± 14 | 0.007 |
| Albumin (g/dL) | 2.6 ± 0.6 | 4.6 ± 0.4 | < 0.001 |
| eGFR (mL/min) (n/%) | 87 ± 22 | 77 ± 18 | 0.001 |
Biochemical data of the survivors’ patients with severe COVID-19 at T0 (date of ICU admission) and 12 months (T12) after ICU discharge
| Variables | T0 | T12 | p |
|---|---|---|---|
| Creatinine (mg/dL) | 1.10 ± 0.47 | 1.12 ± 0.24 | 0.67 |
| Urea (mg/dL) | 39 ± 18 | 41 ± 12 | 0.31 |
| Sodium (Na) (mmol/L) | 137 ± 3 | 141 ± 3 | < 0.001 |
| Potassium (K) (mmol/L) | 3.9 ± 0.6 | 4.4 ± 0.4 | < 0.001 |
| Glucose (mg/dL) | 124 ± 36 | 117 ± 42 | < 0.001 |
| Albumin (g/dL) | 2.5 ± 0.6 | 4.5 ± 0.3 | < 0.001 |
| eGFR (mL/min) (n/%) | 83 ± 23 | 78 ± 18 | 0.07 |
| eGFR ≤ 59 (mL/min) (n/%) | 12/14% | 13/16% | 0.98 |
Epidemiological and clinical data of the severely ill individuals eligible for the study at the time of infection (T0) (n = 82)
| Variables | n = 82 |
|---|---|
| Age (years) | 52 ±12 |
| Gender (male) | 75 (90%) |
| Race (white) | 72 (87%) |
| BMI (Kg/m2) | 31 (22–55) |
| ≥18,5 ate 24,9 Kg/m2 | 9 (11%) |
| ≥25 ate 29,9 kg/m | 27 (33%) |
| ≥30 kg/m2 | 46 (56%) |
| Hospitalization in the ICU (days) | 9 ± 8 |
| Hypertension (%) | 38 (46%) |
| Diabetes Mellitus (%) | 26 (31%) |
| Cardiovascular disease (%) | 5 (6%) |
| Ventilatory support (%) | 15 (18%) |
| Drug Vasoactive use (%) | 20 (24%) |
| Vacination (Doses) (%) | 6 (7%) |
| 0–1 doses | 76 (93%) |
| ≥ 2 doses | |
| Acute kidney disease (%) | 16 (20%) |
| Hemodialysis | 8 (10%) |
SF36 quality of life assessment (SF36 - functional capacity and pain), pain scale (EVA), functional capacity (DASI), muscle strength - dominant handgrip strength (FPP D) and 30-second sit-to-stand test and risk of sarcopenia (SARC - F), 12 months after the date of recovery from COVID 19 (n = 82)
| Variables | T12 |
|---|---|
| Quality of live | |
| SF36 – Funcional Capacity | 47 ± 21 |
| SF36 – Pain | 47 ± 18 |
| Pain Scale | |
| Visual Analog Scale - 5 (n/%) | 47 / 57% |
| Muscle Strenght | |
| Handgrip Strenght (kgf) | 18 ± 6 |
| The 30-second sit-to-stand test | 8 ± 5 |
| Functional Capacity | |
| Duke Activity Status Index (score) | 44 ± 11 |
| Risk of Sarcopenia | |
| SARC – F (escore ≥ 4)(n/%) | 37 / 46% |